CYCN:NASDAQCyclerion Therapeutics, Inc. Analysis

Cyclerion Therapeutics (CYCN) is trading at $1.505, just above its calculated support of $1.28 and below the near‑term resistance of $1.675. The price sits marginally above the 20‑day SMA ($1.48) and the 50‑day SMA ($1.38) but remains well under the 200‑day SMA ($2.05), signaling a neutral longer‑term trend. Technical momentum is modestly bullish with a MACD histogram of +0.006 and an RSI of 53.8, yet volume has been shrinking, and the 30‑day volatility spikes at nearly 47%, underscoring short‑term price fragility.
Fundamentally, CYCN holds $4.57 M in cash with zero debt, but it is burning cash—operating cash flow is –$1.38 M and free cash flow –$1.45 M. Margins are deeply negative (operating margin –115%, profit margin –77%) and earnings per share are –$0.70, resulting in a non‑meaningful PE. However, the price‑to‑book ratio of 0.58 and price‑to‑sales of 2.0 are well below industry averages, and analysts project a median target price of $8, implying a potential upside of over 400%.
Recent news highlights progress on the CYC‑126 Phase 2 proof‑of‑concept study, with FDA feedback and the formation of a clinical advisory board, suggesting a possible catalyst that could re‑ignite investor interest if trial data prove favorable.